Previous studies have documented SMARCA2 mutations or deletion in 5-10% of non-small-cell lung carcinoma (20, 21), 10% of esophageal adenocarcinoma (22), 5-9% of gastric cancer (23, 24), 1.3% of colorectal carcinoma (25), 3% of clear cell renal cell carcinoma (26), and 5% adenoid cystic carcinomas (27). This evidence concerns the gene SMARCA2 and clear cell renal carcinoma.